RS62047B1 - Imunosupresivni agensi i njihova upotreba u terapiji - Google Patents
Imunosupresivni agensi i njihova upotreba u terapijiInfo
- Publication number
- RS62047B1 RS62047B1 RS20210577A RSP20210577A RS62047B1 RS 62047 B1 RS62047 B1 RS 62047B1 RS 20210577 A RS20210577 A RS 20210577A RS P20210577 A RSP20210577 A RS P20210577A RS 62047 B1 RS62047 B1 RS 62047B1
- Authority
- RS
- Serbia
- Prior art keywords
- therapy
- immunosuppressive agents
- immunosuppressive
- agents
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1319620.9A GB201319620D0 (en) | 2013-11-06 | 2013-11-06 | Immunosuppressive agents and their use in therapy |
| EP14793594.4A EP3065759B1 (en) | 2013-11-06 | 2014-11-06 | Immunosuppressive agents and their use in therapy |
| PCT/EP2014/073966 WO2015067712A1 (en) | 2013-11-06 | 2014-11-06 | Immunosuppressive agents and their use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RS62047B1 true RS62047B1 (sr) | 2021-07-30 |
Family
ID=49767770
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RS20210577A RS62047B1 (sr) | 2013-11-06 | 2014-11-06 | Imunosupresivni agensi i njihova upotreba u terapiji |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US10517923B2 (sr) |
| EP (1) | EP3065759B1 (sr) |
| DK (1) | DK3065759T3 (sr) |
| ES (1) | ES2869901T3 (sr) |
| GB (1) | GB201319620D0 (sr) |
| HR (1) | HRP20210792T1 (sr) |
| LT (1) | LT3065759T (sr) |
| PL (1) | PL3065759T3 (sr) |
| PT (1) | PT3065759T (sr) |
| RS (1) | RS62047B1 (sr) |
| WO (1) | WO2015067712A1 (sr) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018140863A1 (en) * | 2017-01-27 | 2018-08-02 | Vanderbilt University | Fused in sarcoma (fus) nuclear translocation inhibitors for preventing fibrosis |
| GB201319621D0 (en) * | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Antimicrobial agents and their use in therapy |
| GB201319620D0 (en) * | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Immunosuppressive agents and their use in therapy |
| GB201507722D0 (en) | 2015-05-06 | 2015-06-17 | Norwegian Univ Sci & Tech Ntnu | Anti-bacterial agents and their use in therapy |
| GB201507721D0 (en) * | 2015-05-06 | 2015-06-17 | Norwegian Univ Sci & Tech Ntnu | Immunosuppressive agents and their use in therapy |
| EP3432908A4 (en) * | 2016-03-21 | 2020-07-29 | Rhode Island Council on Postsecondary Education | PEPTIDES SENSITIVE TO PH |
| WO2020138674A1 (ko) * | 2018-12-26 | 2020-07-02 | (주)케어젠 | 근육 이완용 조성물 |
| MX2020014330A (es) * | 2018-12-26 | 2021-03-09 | Caregen Co Ltd | Composicion para relajacion muscular. |
| KR102456989B1 (ko) * | 2020-06-12 | 2022-10-21 | (주)케어젠 | 항비만 활성을 가지는 디옥시콜산-펩타이드 결합체 및 이의 용도 |
| KR102570768B1 (ko) * | 2020-06-12 | 2023-08-28 | (주)케어젠 | 펜타펩타이드를 유효성분으로 포함하는 다한증 치료용 조성물 |
| KR102483938B1 (ko) * | 2020-06-12 | 2023-01-04 | (주)케어젠 | 펜타펩타이드를 유효성분으로 포함하는 항알러지 또는 아토피피부염 개선용 조성물 |
| CN115916236A (zh) * | 2020-06-12 | 2023-04-04 | 凯尔格恩有限公司 | 包含五肽作为活性成分的组合物 |
| KR102469721B1 (ko) * | 2020-06-12 | 2022-11-23 | (주)케어젠 | 보툴리눔 톡신 유사 활성을 갖는 펩타이드 및 이의 용도 |
| KR102463320B1 (ko) * | 2020-06-12 | 2022-11-07 | (주)케어젠 | 펜타펩타이드를 유효성분으로 포함하는 통증의 완화, 예방 또는 치료용 조성물 |
| US11741686B2 (en) | 2020-12-01 | 2023-08-29 | Raytheon Company | System and method for processing facility image data |
Family Cites Families (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198541A (en) | 1987-08-11 | 1993-03-30 | New York University | Dna encoding bactericidal/permeability-increasing proteins |
| US6316003B1 (en) * | 1989-12-21 | 2001-11-13 | Whitehead Institute For Biomedical Research | Tat-derived transport polypeptides |
| US5643578A (en) | 1992-03-23 | 1997-07-01 | University Of Massachusetts Medical Center | Immunization by inoculation of DNA transcription unit |
| EP0642579B1 (en) | 1992-05-19 | 1999-04-07 | Xoma Corporation | Improved methods for the preparation of endotoxin-binding proteins |
| US5420019A (en) | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
| ES2123134T3 (es) | 1993-03-12 | 1999-01-01 | Xoma Corp | Peptidos biologicamente activos de dominios funcionales de la proteina bactericida aumentadora de la permeabilidad y usos de los mismos. |
| MX9401807A (es) | 1993-03-12 | 1995-01-31 | Xoma Corp | Usos terapeuticos de productos de proteina que incrementan lapermeabilidad/bactericidas. |
| AU7970894A (en) | 1993-10-15 | 1995-05-04 | Xoma Corporation | Method of treating depressed reticuloendothelial system function |
| MX9602570A (es) | 1994-01-14 | 1997-04-30 | Xoma Corp | Metodos y materiales anti-fungosos. |
| AU703192B2 (en) | 1994-01-14 | 1999-03-18 | Xoma Corporation | Anti-gram-positive bacterial methods and materials |
| US5643875A (en) | 1994-01-24 | 1997-07-01 | Friedmann; Nadav | Human therapeutic uses of bactericidal/permeability increasing (BPI) protein products |
| US5447913A (en) | 1994-03-11 | 1995-09-05 | Xoma Corporation | Therapeutic uses of bactericidal/permeability-increasing protein dimer products |
| US5578568A (en) | 1994-04-22 | 1996-11-26 | Xoma Corporation | Method of treating conditions associated with intestinal ischemia/reperfusion |
| US5646114A (en) | 1994-07-11 | 1997-07-08 | Xoma Corporation | Anti-protozoan methods |
| AU709738B2 (en) | 1994-09-15 | 1999-09-02 | Xoma Corporation | Anti-fungal peptides |
| US5912228A (en) | 1995-01-13 | 1999-06-15 | Xoma Corporation | Therapeutic compositions comprising bactericidal/permeability-increasing (BPI) protein products |
| US5494896A (en) | 1995-03-31 | 1996-02-27 | Xoma Corporation | Method of treating conditions associated with burn injuries |
| US6057291A (en) * | 1995-06-02 | 2000-05-02 | University Of British Columbia | Antimicrobial cationic peptides |
| EP0839156A1 (en) | 1995-07-20 | 1998-05-06 | Xoma Corporation | Anti-fungal peptides |
| US5686414A (en) | 1995-11-14 | 1997-11-11 | Xoma Corporation | Methods of treating conditions associated with corneal transplantation |
| US5851802A (en) | 1996-03-22 | 1998-12-22 | Xoma Corporation | Methods for recombinant microbial production of fusion proteins and BPI-derived peptides |
| NZ332720A (en) | 1996-05-10 | 2000-07-28 | Xoma Corp | Therapeutic uses of bactericidal/permeability increasing (BPI) protein to treat human meningococcemia |
| US5741779A (en) | 1996-05-10 | 1998-04-21 | Xoma Corporation | Antithrombotic materials and methods |
| AU736096B2 (en) | 1996-05-23 | 2001-07-26 | Xoma Corporation | Therapeutic uses of BPI protein products in humans with hemorrhage due to trauma |
| US5888973A (en) | 1996-08-09 | 1999-03-30 | Xoma Corporation | Anti-chlamydial uses of BPI protein products |
| EP0938331B1 (en) | 1996-11-01 | 2002-12-18 | XOMA Technology Ltd. | Therapeutic uses of bpi protein products in cystic fibrosis patients |
| US6482796B2 (en) | 1996-11-01 | 2002-11-19 | Xoma Corporation | Therapeutic uses of N-terminal BPI protein products in ANCA-positive patients |
| US6093573A (en) | 1997-06-20 | 2000-07-25 | Xoma | Three-dimensional structure of bactericidal/permeability-increasing protein (BPI) |
| US6013631A (en) | 1998-06-19 | 2000-01-11 | Xoma Corporation | Bactericidal/permeability-increasing protein (BPI) deletion analogs |
| SE512161C2 (sv) | 1998-06-30 | 2000-02-07 | Sandvik Ab | Hårdmetall och användning av denna vid olje- och gasutvinning |
| AU6163099A (en) | 1998-09-25 | 2000-04-17 | Xoma Technology Ltd. | Antifungal and antibacterial peptide |
| WO2000043028A2 (en) | 1999-01-22 | 2000-07-27 | Xoma Technology Ltd. | Method of treating chronic cardiac disease |
| US6153584A (en) | 1999-04-01 | 2000-11-28 | Levy; Ofer | Therapeutic uses of BPI protein products in BPI-deficient humans |
| US6355616B1 (en) | 1999-06-25 | 2002-03-12 | Xoma (Us) Technology Ltd. | Derivative compounds derived from or based on bactericidal/permeability-increasing protein |
| AU4203900A (en) | 1999-07-12 | 2001-01-30 | Xoma Technology Ltd. | Method to identify antimicrobial agents |
| WO2001003724A1 (en) | 1999-07-12 | 2001-01-18 | Xoma Technology Ltd. | Therapeutic uses of bpi protein products for inhibiting h+/k+ atpase activity |
| AU4204800A (en) | 1999-07-12 | 2001-01-30 | Xoma Technology Ltd. | Method to identify inhibitors f1/f0 atpase |
| WO2001004348A1 (en) | 1999-07-12 | 2001-01-18 | Xoma Technology Ltd. | Methods to identify inhibitors of f1/f0 atpase |
| US6777439B2 (en) * | 2000-05-30 | 2004-08-17 | Advanced Research & Technology Institute, Inc. | Compositions and methods for identifying agents which modulate PTEN function and PI-3 kinase pathways |
| US20030166528A1 (en) | 2000-10-11 | 2003-09-04 | Jong-Jye Lin | Antifungal compound |
| AU2002241589B2 (en) | 2000-12-01 | 2007-07-19 | Xoma Technology Ltd. | Modulation of pericyte proliferation using BPI protein products or BPI inhibitors |
| JP4310107B2 (ja) | 2001-03-28 | 2009-08-05 | ヘリックス バイオメディックス，インコーポレイテッド | 生物活性を有する短ペプチド及び該ペプチドの使用方法 |
| US7517857B2 (en) | 2002-01-29 | 2009-04-14 | Posco | Immune-modulating peptide |
| WO2005068504A1 (ja) * | 2004-01-19 | 2005-07-28 | Medical And Biological Laboratories Co., Ltd. | 炎症性サイトカイン抑制剤 |
| KR20080023680A (ko) * | 2005-05-10 | 2008-03-14 | 인터뮨, 인크. | 스트레스-활성화 단백질 키나제 시스템을 조절하기 위한피리돈 유도체 |
| US7612181B2 (en) * | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| US7579318B2 (en) * | 2005-12-06 | 2009-08-25 | Centre De La Recherche De La Scientifique | Cell penetrating peptides for intracellular delivery of molecules |
| US20110038856A1 (en) * | 2006-11-02 | 2011-02-17 | Seattle Genetics, Inc. | Methods of treating neoplastic, autoimmune and inflammatory diseases |
| US8419332B2 (en) * | 2007-10-19 | 2013-04-16 | Atlas Bolt & Screw Company Llc | Non-dimpling fastener |
| GB0803352D0 (en) * | 2008-02-22 | 2008-04-02 | Ntnu Technology Transfer As | Oligopeptidic compounds and uses thereof |
| CA2744120A1 (en) * | 2008-11-17 | 2010-05-20 | The Provost, Fellows, Foundation Scholars, And The Other Members Of Boar D, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth, | A vaccinia virus protein a46 peptide and use thereof |
| GB0916576D0 (en) * | 2009-09-22 | 2009-10-28 | Malmsten Nils M | Polypeptides and uses thereof |
| AT510991A5 (de) * | 2009-10-09 | 2015-02-15 | Kemijski Inst | Peptide für die Inhibition MyD88-abhängiger Signalwege |
| WO2011104309A1 (en) * | 2010-02-24 | 2011-09-01 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Compounds for the treatment of inflammation and neutropenia |
| WO2012154814A1 (en) * | 2011-05-09 | 2012-11-15 | Eip Pharma, Llc | Compositions and methods for treating alzheimer's disease |
| WO2012177892A2 (en) * | 2011-06-21 | 2012-12-27 | University Of Florida Research Foundation, Inc. | Type i interferon mimetics as therapeutics for cancer, viral infections, and multiple sclerosis |
| CA2878701C (en) * | 2011-07-12 | 2022-05-17 | The University Of British Columbia | Neuroprotective pepties that inhbit interaction between palmitoyl acyl transferase zinc-finger dhhc type containing 17 (zd17) and c-jun n-terminal kinase (jnk) |
| WO2013110005A1 (en) * | 2012-01-18 | 2013-07-25 | Wisconsin Alumni Research Foundation | Boronate-mediated delivery of molecules into cells |
| KR101497972B1 (ko) * | 2012-03-21 | 2015-03-03 | 서울대학교산학협력단 | Ｎｏｄ2 신호전달 경로를 표적으로 하는 패혈증 치료제 스크리닝 방법 및 패혈증 치료제 |
| GB201319621D0 (en) * | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Antimicrobial agents and their use in therapy |
| GB201319620D0 (en) * | 2013-11-06 | 2013-12-18 | Norwegian University Of Science And Technology | Immunosuppressive agents and their use in therapy |
-
2013
- 2013-11-06 GB GBGB1319620.9A patent/GB201319620D0/en not_active Ceased
-
2014
- 2014-11-06 RS RS20210577A patent/RS62047B1/sr unknown
- 2014-11-06 PT PT147935944T patent/PT3065759T/pt unknown
- 2014-11-06 EP EP14793594.4A patent/EP3065759B1/en active Active
- 2014-11-06 DK DK14793594.4T patent/DK3065759T3/da active
- 2014-11-06 LT LTEP14793594.4T patent/LT3065759T/lt unknown
- 2014-11-06 PL PL14793594T patent/PL3065759T3/pl unknown
- 2014-11-06 US US15/034,917 patent/US10517923B2/en active Active
- 2014-11-06 WO PCT/EP2014/073966 patent/WO2015067712A1/en active Application Filing
- 2014-11-06 ES ES14793594T patent/ES2869901T3/es active Active
-
2019
- 2019-11-13 US US16/683,188 patent/US11246907B2/en active Active
-
2021
- 2021-05-17 HR HRP20210792TT patent/HRP20210792T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| GB201319620D0 (en) | 2013-12-18 |
| WO2015067712A1 (en) | 2015-05-14 |
| DK3065759T3 (da) | 2021-05-17 |
| US11246907B2 (en) | 2022-02-15 |
| EP3065759A1 (en) | 2016-09-14 |
| HRP20210792T1 (hr) | 2021-08-20 |
| US10517923B2 (en) | 2019-12-31 |
| EP3065759B1 (en) | 2021-03-31 |
| LT3065759T (lt) | 2021-08-10 |
| US20200323953A1 (en) | 2020-10-15 |
| PT3065759T (pt) | 2021-05-17 |
| US20160279193A1 (en) | 2016-09-29 |
| PL3065759T3 (pl) | 2021-10-25 |
| ES2869901T3 (es) | 2021-10-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT3065759T (lt) | Imunosupresiniai agentai ir jų panaudojimo terapija | |
| HK1221474A1 (zh) | 多粘菌素衍生物及其在與不同抗生素的組合療法中的用途 | |
| IL246221A0 (en) | Endazoles and their uses | |
| GB201319621D0 (en) | Antimicrobial agents and their use in therapy | |
| IL240248A0 (en) | Met-binding substances and their uses | |
| IL239904A0 (en) | Inhibitory oligonucleotides and their use in therapy | |
| IL245597B (en) | Anti-neuroinflammatory and protective compounds in Achillea fragrantissima - implications for inflammatory and neurodegenerative diseases | |
| HK1222561A1 (zh) | 用於腫瘤學的組合物和方法 | |
| GB2515865B (en) | Use of galactooligosaccharides in therapy | |
| EP2853591A4 (en) | HEMATOMIC HEMAZONE CELL LINE HLCZ01 AND USES THEREOF | |
| GB201310921D0 (en) | Peptide-resin conjugate and use thereof | |
| GB201305940D0 (en) | Methods and arrays for use in the same | |
| GB201507721D0 (en) | Immunosuppressive agents and their use in therapy | |
| GB201308753D0 (en) | Compounds and their use in therapy | |
| IL243091B (en) | Compositions and methods for use in oncology | |
| HK1209033A1 (zh) | 奧地帕西在治療黏多醣症病中的應用 | |
| GB201319273D0 (en) | Improvements in structural members and methods relating thereto | |
| GB201322869D0 (en) | Therapeutic agents and delivery with microspheres | |
| GB201304038D0 (en) | Treated cells and therapeutic uses | |
| GB201308217D0 (en) | Compounds and their use in therapy | |
| IL244576A0 (en) | Anti-vstm5 antibodies and their use for treatment and diagnosis | |
| GB201312129D0 (en) | Drug combination and its use in therapy | |
| GB201312128D0 (en) | Drug combination and its use in therapy | |
| GB201312131D0 (en) | Drug combination and its use in therapy | |
| AU2013901916A0 (en) | An Agent and Use Thereof in Therapy |